New clinical trial results for treatment of COVID-19 outpatients

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecules and biological therapies, announced the enrollment and dosing of its first patient in China in its multi-regional Phase III clinical trial (NCT04869228) of proxalutamide for the treatment of COVID-19 outpatients at Shenzhen Third People’s Hospital in China on February 10, 2022.

The Phase III trial is a randomized, double-blind, placebo-controlled, multi-regional study designed to evaluate the efficacy and safety of proxalutamide in male outpatients with COVID-19. The phase III trial has enrolled nearly 200 patients at sites in countries including Brazil, the Philippines and Malaysia. China is one of the main countries participating in this multi-regional trial, which was approved by the NMPA of China on September 1, 2021. Sites participating in this trial in China include Beijing Ditan Hospital, Beijing Hospital, China-Japan friendship, the third Shenzhen People’s Hospital, Shanghai Public Health Clinical Center, Hangzhou Xixi Hospital, Chengdu Public Health Clinical Center and Suzhou Fifth People’s Hospital.

Dr. Tong Youzhi, Founder, Chairman and CEO of Kintor Pharma, said, “We would especially like to thank Chairman Dr. Hongzhou Lu and his team at Shenzhen Third People’s Hospital for the initial patient recruitment and assay in the phase III clinical trial of proxalutamide for the treatment of COVID-19 outpatients in China, which is a very important milestone for this multi-regional clinical trial. We will do our best to invite more sites in China to join this crucial study. Additionally, the COVID-19 Inpatient Clinical Trial (NCT05009732) has initiated patient recruitment in the United States, Ukraine and the Philippines, and is currently screening patients prior to recruitment at sites in China. . We are also actively pursuing the process in the rest of the countries participating in our multi-regional clinical trials. »

Elna M. Lemons